Eloxx Pharmaceuticals to Present at the 3rd Annual Guggenheim Healthcare Innovation Conference
PR Newswire•02/11/2026•16:15 ET
0
Key Highlights
- ➤Eloxx (ELOX) CEO to present at Guggenheim Healthcare Innovation Conference November 9
- ➤Presentation scheduled for 11:30–11:55 a.m. ET on November 9
- ➤Exaluren targets rare kidney diseases, including nonsense mutation Alport syndrome
- ➤Eloxx exclusively licensed ZKN-013 to Almirall for rare dermatological diseases
Eloxx Pharmaceuticals to Present at the 3rd Annual Guggenheim Healthcare Innovation Conference PR Newswire
ARLINGTON, Mass., Nov. 2, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced that Sumit Aggarwal, President and Chief Executive Officer, will present at the 3rd Annual Guggenheim Healthcare Innovation Conference, taking place November 9–11, 2026.
Get started
Create a free account to read the full story.